Pacira BioSciences Divests iovera® Business to Zimmer Biomet for Up to $140M, Bolstering Balance Sheet
PCRX sits 36% above its 52-week low of $18.8.
Summary
Pacira BioSciences is selling its iovera® cryoanalgesia business to Zimmer Biomet for up to $140 million, with $70 million upfront, to strengthen its balance sheet and focus on its biopharmaceutical pipeline.
Key Events · M&A and Partnerships · PCRX
-
Divestiture Agreement
Pacira BioSciences entered into an agreement to sell its iovera® cryoanalgesia business and Pacira CryoTech, Inc. to Zimmer Biomet.
-
Transaction Value
The deal is valued at up to $140 million, comprising an upfront payment of $70 million and up to $70 million in potential revenue-based milestone payments through 2031.
-
Strategic Focus
The divestiture supports Pacira's "5x30 strategy" to transition into an innovative biopharmaceutical company, streamlining its product portfolio.
-
Balance Sheet Impact
The company intends to use the upfront net proceeds to strengthen its balance sheet, including paying down its senior secured revolving credit facility.
Analysis · PCRX · Life Sciences
This divestiture of the iovera® cryoanalgesia business for up to $140 million, including $70 million upfront, represents a significant strategic move for Pacira BioSciences. The company plans to use the upfront proceeds to strengthen its balance sheet and pay down debt, which is a positive for financial stability. This transaction aligns with Pacira's stated "5x30 strategy" to transition into an innovative biopharmaceutical company, streamlining its portfolio and focusing on core assets. This action comes amidst a recent proxy battle, potentially demonstrating management's commitment to value creation and strategic focus.
At the time of this filing, PCRX was trading at $25.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $986.9M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.